GLS inhibition significantly decreased CFPAC-1, but not MDA-MB-231 or NCI-H441 cell survival, suggesting that pancreatic cancer cells are considerably more sensitive to GLS inhibition when ENO1 function is impaired (Supplementary Figure S10A). This evidence concerns the gene ENO1 and familial pancreatic carcinoma.